Literature DB >> 24000293

miR-141 Regulates colonic leukocytic trafficking by targeting CXCL12β during murine colitis and human Crohn's disease.

Zhen Huang1, Tongguo Shi1, Qian Zhou1, Song Shi1, Ran Zhao1, Hao Shi1, Lei Dong1, Chenyu Zhang1, Ke Zeng1, Jiangning Chen2, Junfeng Zhang1.   

Abstract

OBJECTIVE: Emerging evidence suggests that microRNA (miRNA)-mediated gene regulation influences a variety of autoimmune disease processes, including Crohn's disease (CD), but the biological function of miRNAs in CD remains unclear. We examine miRNA level in colon tissues and study the potential functions of miRNAs that regulate pathological genes during the inflammation process.
DESIGN: miRNA levels were assayed in the inflamed colon of 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced and IL-10 knockout (KO) chronic colitis mice and CD patients by microarray or qRT-PCR. The influence of differently expressed miR-141 on its putative target genes, CXCL12β, and leukocyte migration was investigated in colonic epithelia cells, colitis models and CD patients. The role of miR-141 was further studied in the experimental colitis mice by intracolonic administration of miR-141 precursors or inhibitors.
RESULTS: An inverse correlation between miR-141 and CXCL12β/total-CXCL12 was observed predominantly in the epithelial cells of the inflamed colons from colitic mice and CD patients. Further study demonstrated that miR-141 directly regulated CXCL12β expression and CXCL12β-mediated leukocyte migration. Upregulation or downregulation of miR-141 in the TNBS-induced or IL-10 KO colitic colon regulated leukocyte infiltration and alleviated or aggravated experimental colitis, respectively. Additionally, colonic overexpression of CXCL12β abolished the therapeutic effect of miR-141 in TNBS-induced colitis.
CONCLUSIONS: This study showed that the pathway of miR-141 targeting CXCL12β is a possible mechanism underlying inflammatory cell trafficking during colonic inflammation process. Inhibiting colonic CXCL12β expression and blocking colonic immune cell recruitment by using miRNA precursors represents a promising approach that may be valuable for CD treatment. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  Chemokines; Crohn'S Disease

Mesh:

Substances:

Year:  2013        PMID: 24000293     DOI: 10.1136/gutjnl-2012-304213

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  66 in total

Review 1.  Role of G protein-coupled receptors-microRNA interactions in gastrointestinal pathophysiology.

Authors:  Ivy Ka Man Law; David Miguel Padua; Dimitrios Iliopoulos; Charalabos Pothoulakis
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-08-03       Impact factor: 4.052

2.  MicroRNA-193a-3p Reduces Intestinal Inflammation in Response to Microbiota via Down-regulation of Colonic PepT1.

Authors:  Xin Dai; Xi Chen; Qun Chen; Lei Shi; Hongwei Liang; Zhen Zhou; Qian Liu; Wenjing Pang; Dongxia Hou; Cheng Wang; Ke Zen; Yaozong Yuan; Chen-Yu Zhang; Lu Xia
Journal:  J Biol Chem       Date:  2015-04-30       Impact factor: 5.157

3.  MicroRNA-133α regulates neurotensin-associated colonic inflammation in colonic epithelial cells and experimental colitis.

Authors:  Ivy Ka Man Law; Charalabos Pothoulakis
Journal:  RNA Dis       Date:  2015

Review 4.  Role of MiRNAs in Inflammatory Bowel Disease.

Authors:  Bo Cao; Xin Zhou; Jiaojiao Ma; Wei Zhou; Wanli Yang; Daiming Fan; Liu Hong
Journal:  Dig Dis Sci       Date:  2017-04-08       Impact factor: 3.199

Review 5.  Can We Target Endogenous Anti-inflammatory Responses as a Therapeutic Strategy for Inflammatory Bowel Disease?

Authors:  Ross John Porter; Caroline Andrews; Daniel Paul Brice; Scott Kenneth Durum; Mairi Hall McLean
Journal:  Inflamm Bowel Dis       Date:  2018-09-15       Impact factor: 5.325

Review 6.  Functional role and therapeutic targeting of microRNAs in inflammatory bowel disease.

Authors:  Artin Soroosh; Marina Koutsioumpa; Charalabos Pothoulakis; Dimitrios Iliopoulos
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-11-16       Impact factor: 4.052

Review 7.  MicroRNAs in mucosal inflammation.

Authors:  Viola Neudecker; Xiaoyi Yuan; Jessica L Bowser; Holger K Eltzschig
Journal:  J Mol Med (Berl)       Date:  2017-07-20       Impact factor: 4.599

Review 8.  Mini but mighty: microRNAs in the pathobiology of periodontal disease.

Authors:  Moritz Kebschull; Panos N Papapanou
Journal:  Periodontol 2000       Date:  2015-10       Impact factor: 7.589

Review 9.  MicroRNAs: how many in inflammatory bowel disease?

Authors:  Jeremy S Schaefer
Journal:  Curr Opin Gastroenterol       Date:  2016-07       Impact factor: 3.287

Review 10.  MicroRNAs: Novel immunotherapeutic targets in colorectal carcinoma.

Authors:  Xiang Li; Jing Nie; Qian Mei; Wei-Dong Han
Journal:  World J Gastroenterol       Date:  2016-06-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.